Related Experiment Videos
A within-subject analysis of carbamazepine disposition related to development in children with epilepsy
Insights
Childhood aging affects carbamazepine (CBZ) levels. The CBZ plasma level/dose ratio increases with age, particularly during puberty, indicating physiological changes influence drug metabolism.
Area of Science:
- Pharmacology
- Pediatric Medicine
- Clinical Pharmacy
Background:
- Carbamazepine (CBZ) is a widely used antiepileptic drug.
- Understanding age-related changes in CBZ pharmacokinetics is crucial for optimizing pediatric treatment.
- Previous studies have examined between-patient variability in CBZ levels, but within-subject changes during aging require further investigation.
Purpose of the Study:
- To retrospectively evaluate the effect of aging on the carbamazepine (CBZ) plasma level/dose ratio in children.
- To analyze longitudinal changes in CBZ pharmacokinetics within individual pediatric patients.
Main Methods:
- Retrospective analysis of 15 children on CBZ monotherapy with at least 3 years of follow-up.
- Data sourced from a 12-year period of a therapeutic drug monitoring service.
- Evaluation of the CBZ plasma level/dose ratio in relation to age and pubertal development.
Main Results:
- The CBZ plasma level/dose ratio showed a significant increase within subjects during childhood.
- This increase was not linear with age, with the most pronounced changes observed between 9 and 13 years of age.
- Weight gain alone did not account for the observed changes, suggesting pubertal physiological alterations are involved.
Conclusions:
- Aging and pubertal development significantly impact carbamazepine pharmacokinetics in children.
- The non-linear increase in the CBZ level/dose ratio highlights the need for age- and development-specific dosing adjustments.
- Further research into the physiological mechanisms underlying these changes is warranted for improved therapeutic drug monitoring in pediatric epilepsy.
Abstract:
The effect of aging on carbamazepine (CBZ) plasma level/dose ratio was evaluated retrospectively in 15 children who were receiving CBZ monotherapy and who were followed up for at least 3 years. Subjects of the study were selected from a population of roughly 4,500 patients attending our therapeutic drug monitoring service during a 12-year period. Results showed that the CBZ plasma level/dose ratio increases within subject during childhood, in agreement with data obtained in between-patient studies. However, the increase is not linear with age, the greatest modifications being observed between 9 and 13 years of age. Weight gain alone does not seem to explain this finding, implicating the involvement of complex physiological changes occurring during puberty.